The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study).
 
Akihiko Shimomura
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly Japan
Research Funding - Novartis (Inst)
 
Kenji Tamura
No Relationships to Disclose
 
Tomonori Mizutani
No Relationships to Disclose
 
Taro Shibata
No Relationships to Disclose
 
Fumikata Hara
Honoraria - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Pfizer
 
Tomomi Fujisawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Novartis; Taiho Pharmaceutical
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Novartis
Research Funding - Bristol-Myers Squibb; Chugai Pharma (Inst); Daiichi Sankyo; MSD; Nihon Medi-Physics
 
Takashi Hojo
No Relationships to Disclose
 
Chizuko Kanbayashi
No Relationships to Disclose
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Kyowa Hakko Kirin; Novartis
Research Funding - Chugai Pharma; Daiichi Sankyo
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Masataka Sawaki
No Relationships to Disclose
 
Naohito Yamamoto
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Nippon Kayaku (Inst); Pfizer (Inst)
 
Fumio Nagashima
Speakers' Bureau - Chugai Pharma; Janssen; Kyowa Hakko Kirin; Merck Serono; Mitsubishi Tanabe Pharma; Nestle health science; Ono Pharmaceutical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Tadahiko Shien
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Novartis
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Nihonkayaku; Novartis; Pfizer; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)